Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23


112TiP - SOLTI-1710 PROMETEO II: Palbociclib in combination with letrozole in patients with hormone receptor-positive (HR+)/HER2-negative residual disease after standard neoadjuvant chemotherapy (NAC)


24 May 2020




Eva Ciruelos


Annals of Oncology (2020) 31 (suppl_2): S48-S53. 10.1016/annonc/annonc119


E.M. Ciruelos1, X. González-Farré2, A. Perelló3, E. Alba4, P. Palacios-Ozores5, J. Salvador-Bofil6, M. Merino7, P. Villagrasa8, P. Celiz8, T. Pascual8, A. Prat9, S. Pernas Simon10

Author affiliations

  • 1 Dept. Medical Oncology, Hospital 12 de octubre, 28041 - Madrid/ES
  • 2 Dept. Medical Oncology, Hospital General de Catalunya, 08195 - San Cugat del Valles/ES
  • 3 Dept. Medical Oncology, Hospital Universitari Son Espases, 07120 - Palma de Mallorca/ES
  • 4 Dept. Medical Oncology, Hospital Virgen de la Victoria, 29010 - Málaga/ES
  • 5 Dept. Medical Oncology, Hospital Clínico Universitario de Santiago, 15706 - Santiago de Compostela/ES
  • 6 Dept. Medical Oncology, Hospital Virgen del Rocío, 41013 - Sevilla/ES
  • 7 Dept. Medical Oncology, Hospital Universitario Infanta Sofía, 28703 - San Sebastián de los Reyes/ES
  • 8 Dept. Scientific, SOLTI Breast Cancer Research Group, 08008 - Barcelona/ES
  • 9 Medical Oncology Department, Hospital Clinic y Provincial de Barcelona, 08036 - Barcelona/ES
  • 10 Dept. Medical Oncology, Institut Catala d’ Oncologia, 08908 - Hospitalet de Llobregat/ES

Abstract 112TiP


Despite the improvement in the treatment of early-stage breast cancer (BC) with chemotherapy, many patients have residual disease with a higher risk of metastatic recurrence and poorer outcome than those who achieve a pathological complete response (pCR), particularly in highly proliferative tumors. In HR+ BC, the pCR rates after NAC are around 10-15%. Additional therapeutic strategies to eradicate these residual tumor cells are needed. The combination of cyclin-dependent kinase inhibitors with first or second-line endocrine therapy are options for metastatic BC and its role in the early-setting is being evaluated in several studies. Posttreatment Ki67 levels provide prognostic information for patients with HR+ BC and residual disease, but the prospective validation of this biomarker is necessary. We hypothesize that palbociclib plus letrozole offers antiproliferative benefit in the pre-surgery setting for patients with residual disease and high risk of recurrence.

Trial design

SOLTI1710 PROMETEO II is a prospective single-arm window of opportunity trial in HR+/HER2-negative operable BC patients with residual disease after NAC designed to evaluate the biological effect of palbociclib plus letrozole and to identify biomarkers for better patient selection. Patients must have histologically confirmed HR+/ HER2-negative tumors and locally assessed baseline Ki-67 > 10%, have completed ≥80% total dose of an anthracycline/taxane-based NAC; and residual disease ≥ 1 cm by magnetic resonance imaging and Ki67% ≥ 10% after NAC. Patients will be administered palbociclib at a dose of 125 mg/day, 3 weeks on/1 week off and letrozole 2.5 mg/day continuously, one cycle of treatment. After the neoadjuvant treatment, patients will undergo surgery. Tumor tissue and blood samples will be collected for correlative translational studies. The primary endpoint is the Complete Cell Cycle Arrest (CCCA) determined by Ki67<2.7%, centrally assessed at surgery. Secondary endpoints include rate of RCB 0/1 and pCR after neoadjuvant treatment and adverse events. Recruitment of the planned 20 patients is ongoing in 8 sites across Spain.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

SOLTI Breast Cancer Research Group.




E.M. Ciruelos: Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Advisory/Consultancy: Lilly; Advisory/Consultancy: Novartis; Advisory/Consultancy: Pfizer. X. González-Farré: Travel/Accommodation/Expenses: Roche; Travel/Accommodation/Expenses: Eisai. P. Villagrasa: Speaker Bureau/Expert testimony: NanoString. A. Prat: Advisory/Consultancy, Research grant/Funding (institution): Novartis; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Lilly; Advisory/Consultancy: NanoString; Advisory/Consultancy, Research grant/Funding (institution): Amgen; Advisory/Consultancy, Research grant/Funding (institution): Roche; Advisory/Consultancy: Oncolytics; Advisory/Consultancy: Daiichi Sankyo; Advisory/Consultancy: Puma; Advisory/Consultancy: BMS. S. Pernas Simon: Travel/Accommodation/Expenses: Roche; Advisory/Consultancy: Poliphor. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings